Peptides for Recovery and Performance in Athletic Patients: What the Research Supports

Athletic patients ask about peptides differently than other patients do. They have usually already read something online, they want faster recovery between training blocks, and they are often willing to try things the research has not fully caught up to. That combination makes the provider conversation harder, not easier. The honest version of this topic separates what the human research actually supports from what is still preclinical, and it does not skip the part most articles leave out: several of the peptides athletes hear about are banned in competitive sport. Here is the clinical picture, mechanism by mechanism, and the compliance line that protects both the patient and the practice.

What "Recovery and Performance" Peptides Actually Refers To

The category is not one thing. When a patient says "peptides for recovery," they are usually pointing at three different groups of molecules that work through different biology and sit at very different levels of evidence.

The first group is connective-tissue support, led by collagen peptides, which act on the extracellular matrix of tendon, ligament, and muscle. The second is the tissue-repair peptides such as BPC-157 and thymosin beta-4, studied largely in animal and laboratory models for soft-tissue healing. The third is the growth hormone axis, reached through growth hormone secretagogues that prompt the body to release its own growth hormone and insulin-like growth factor-1 (IGF-1). Lumping these together is the most common mistake in patient conversations, because the strength of the evidence drops sharply as you move from the first group to the third.

Collagen Peptides: The Strongest Human Evidence

Of everything in this category, collagen peptides have the most human data, and the data is reasonably encouraging when the supplement is paired with training rather than used on its own. A 2024 systematic review with meta-analysis in Sports Medicine found that long-term collagen peptide supplementation combined with physical training was associated with significant improvements in fat-free mass, tendon structure, muscle organization, maximal strength, and recovery of reactive strength following exercise-induced muscle damage.¹ A 2025 randomized controlled trial in Medicine & Science in Sports & Exercise reported that 16 weeks of daily collagen peptide intake increased both muscle and tendon stiffness and was associated with gains in explosive strength in young men.²

Two qualifiers matter for any patient conversation. First, the benefits in the literature show up alongside a training stimulus, not in place of one. Collagen peptides appear to support the connective-tissue remodeling that training drives; they are not a substitute for the training. Second, these are connective-tissue and strength-adaptation findings over weeks to months, not overnight recovery effects. A patient expecting to feel different after a single dose has the wrong model of how this works.

BPC-157 and Tissue Repair: Robust Preclinical, Still Investigational

BPC-157 generates more patient questions than almost any other peptide, largely because the preclinical results are striking. In animal and cell models the peptide supports angiogenesis, collagen synthesis, and fibroblast activity, with documented effects on tendon, muscle, and ligament healing. One laboratory study found that BPC-157 increased growth hormone receptor expression in tendon fibroblasts, a mechanism the authors proposed could potentiate the proliferation-promoting effect of growth hormone on tendon tissue.⁴ That is a plausible and interesting mechanism, but it is an in vitro finding in isolated cells, not a clinical outcome in a patient.

This is exactly where providers should slow down. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine summarized the situation directly: BPC-157 shows robust regenerative effects in preclinical studies, but human evidence remains limited to a small number of pilot studies, and the peptide should be considered investigational pending well-designed clinical trials.³ The accurate framing for a patient is that the animal data is genuinely interesting and the human data is not yet there. Describing it any other way overstates what is known. For the fuller breakdown of where BPC-157 evidence is strong and where it stops, see what the BPC-157 research actually shows.

The Growth Hormone Axis: Pharmacology, Not a Supplement

Growth hormone secretagogues, including ghrelin mimetics and growth hormone-releasing peptides, work by stimulating the body's own release of growth hormone, which raises IGF-1. A 2018 review in Sexual Medicine Reviews reported that these agents can increase GH and IGF-1 levels, with effects on body composition and sleep architecture, but the same review flagged concerns around glucose metabolism and called for further study of long-term safety, including cancer-related outcomes.⁵ These are pharmacologic agents with a meaningful side-effect profile, not benign recovery aids, and the long-term safety picture is not settled. The sleep-and-recovery connection is real in the literature but should be presented with that caution intact. Our overview of peptides for sleep and recovery goes deeper on the GH-pathway mechanisms and their limits.

Why Delivery Format Matters for Active Patients

Adherence is part of recovery, and the delivery route shapes adherence. A peptide swallowed as a capsule faces a hostile path: review literature on oral peptide delivery identifies enzymatic hydrolysis and poor permeation across the intestinal mucosa as the dominant reasons systemic absorption of swallowed peptides is so low.⁶ That is the historical reason many therapeutic peptides have required injection. For an athletic patient who trains daily and travels for competition, a needle-and-cold-chain protocol is a real adherence obstacle. An oral dissolving format that a patient will actually take consistently has practical value, provided the expectations around what the peptide can and cannot do are set honestly. For the route-by-route detail, see sublingual versus injectable bioavailability.

The Compliance Line Every Provider With Athletes Must Know

This is the section most peptide content omits, and it is the one that protects a competitive athlete's eligibility and your practice's reputation. Several of the peptides discussed here are prohibited in sport. Under the World Anti-Doping Agency Prohibited List, growth hormone secretagogues and growth hormone-releasing peptides are banned at all times under category S2, as is thymosin beta-4 and its derivatives, the family that includes the commonly marketed TB-500.⁷ BPC-157 is not listed by name, but it is widely understood to fall under the same growth-factor provisions and has drawn anti-doping scrutiny.

The practical takeaway is not that these molecules are unsafe by definition; it is that prescribing or recommending them to a patient who competes under an anti-doping authority can end that patient's eligibility regardless of intent. Any patient who competes in a sanctioned sport, at any level from collegiate to masters, needs to hear this before anything else. A provider who knows the list and raises it first earns trust; a provider who learns about it after a positive test does not. When in doubt, check the current Prohibited List directly, because it is updated annually.

How Providers Actually Use This in Practice

The clinics that handle athletic peptide conversations well tend to do the same few things. They lead with the compliance question for any competitive athlete. They reserve their most confident language for the area with the strongest human evidence, connective-tissue support paired with training, and they explicitly label the rest as mechanism-level or preclinical. They set time-course expectations so patients are not waiting for an effect the biology does not produce quickly. And they document the conversation, including what was and was not claimed.

None of that requires overclaiming. It requires knowing which group a given peptide belongs to and matching the strength of the claim to the strength of the evidence. That is also what keeps the conversation compliant, because describing mechanisms and published research is a very different act than promising an outcome. Practices that already run this kind of structured conversation, including many chiropractic practices using peptides for recovery and performance, find that the restraint is what builds patient confidence rather than undermining it.

The Bottom Line for Practices

Peptides occupy a real but narrow place in recovery and performance support for athletic patients. Collagen peptides have the most human evidence and work as an adjunct to training, not a replacement for it. BPC-157 and the tissue-repair peptides are mechanistically interesting and still investigational in humans. Growth hormone secretagogues are pharmacologic agents with unsettled long-term safety. And several of these molecules are prohibited in competitive sport, which has to be the first question for any athlete, not an afterthought. Providers who hold those distinctions are the ones who can have this conversation safely and credibly.

The oral dissolving strips in our wholesale program use patented InstaRelease® technology by InstaMed, engineered for mucosal residence and dissolution. Apply for a free wholesale account.

References

1. Bischof K, Moitzi AM, Stafilidis S, König D. Impact of Collagen Peptide Supplementation in Combination with Long-Term Physical Training on Strength, Musculotendinous Remodeling, Functional Recovery, and Body Composition in Healthy Adults: A Systematic Review with Meta-analysis. Sports Med. 2024;54(11):2865-2888. PubMed: 39060741
2. Miyamoto N, Ishihara K, Oshima T, Kawai M, Oritani Y, Iemoto N. Collagen Peptide Supplementation Enhances Muscle-Tendon Stiffness and Explosive Strength: A 16-wk Randomized Controlled Trial. Med Sci Sports Exerc. 2025;57(12):2877-2886. PubMed: 40623147
3. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PubMed: 40789979
4. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PubMed: 25415472
5. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PubMed: 28400207
6. Mehrotra S, Kalyan Bg P, Nayak PG, Joseph A, Manikkath J. Recent Progress in the Oral Delivery of Therapeutic Peptides and Proteins: Overview of Pharmaceutical Strategies to Overcome Absorption Hurdles. Adv Pharm Bull. 2024;14(1):11-33. PubMed: 38585454
7. World Anti-Doping Agency. The Prohibited List (S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics). wada-ama.org/en/prohibited-list

Disclaimer: This article is for educational purposes for healthcare providers and is not medical advice. Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Evidence varies by peptide, formulation, dose, and individual, and much of the data discussed is preclinical. Several peptides referenced here are prohibited in competitive sport. Providers are responsible for evaluating products, anti-doping status, and clinical use within their own scope of practice and applicable regulations.